PD-L1 is known to be a prominent negative regulator of T cell functions and a mediator of immune evasion by tumour cells.81 Inhibition of signalling by PD-L1 or another immune-checkpoint component, CTLA-4, has proven to be beneficial for cancer patient survival. This evidence concerns the gene CTLA4 and cancer.